Clinical Trial: A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07538804) titled 'A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer' on April 13.

Brief Summary: This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.

Study Start Date: June 09

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer

Intervention: DRUG: ANS02

ANS02 is a novel, non-covalent, mutant-selective macrocyclic, brain-penetrant, oral EGFR TKI.

Recruitment Status: NOT_YET_RECRUITING

Spo...